Ambrisentan - Isotope Labelled Standards
References
FAQ's
References
- Riechers, Hartmut; Klinge, Dagmar; Amberg, Wilhelm; Kling, Andreas; Mueller, Stefan; Baumann, Ernst; Rheinheimer, Joachim; Vogelbacher, Uwe Josef; Wernet, Wolfgang; Unger, Liliane; et al, Carboxylic acid derivatives, their preparation and use, Abbott Gmbh & Co. KG, Germany, US7109205B2, September 19, 2006
- Ramisetti, Nageswara Rao; Kuntamukkala, Ramakrishna, LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method, New Journal of Chemistry, Volume: 38, Issue: 7, Pages: 3050-3061, 2014
Frequently Asked Questions
Why is it vital to analyze Ambrisentan impurities?
Analyzing impurities in Ambrisentan is critical to ensure the drug's safety and effectiveness. They can affect drug quality, stability, and safety reducing its efficacy or causing harm to patients. Analyzing impurities can help identify their sources, enabling manufacturers to control their formation.
What steps can manufacturers take to control impurity levels in Ambrisentan?
Manufacturers can take various steps to control impurity levels in Ambrisentan, including using high-quality starting materials, optimizing reaction conditions, implementing effective purification techniques, and monitoring impurity levels throughout the manufacturing process.
Which solvent helps in the analysis of Ambrisentan impurities?
Methanol is a solvent that helps in analyzing many impurities in Ambrisentan.
What are the temperature conditions required to store Ambrisentan impurities?
Ambrisentan impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.